Who is sponsoring NCT06707896?

NCT06707896 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT06707896?

Interventions in NCT06707896: TCR1020-CD8 T cells.

What condition does NCT06707896 study?

NCT06707896 studies Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer.

Is NCT06707896 still recruiting?

NCT06707896 is currently withdrawn. Last updated 25 June 2025.

Last reviewed 2025-06-25 · How we verify

NCT06707896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TCR1020-CD8 T Cells in KRAS-mutated Cancers

Withdrawn Phase 1 Last updated 25 June 2025

What this trial tests

Phase 1 trial testing TCR1020-CD8 T cells in Metastatic Pancreatic Adenocarcinoma. Withdrawn.

Timeline

1 June 2025

Primary endpoint
1 February 2029

1 February 2044

Quick facts

Lead sponsor	University of Pennsylvania
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 June 2025
Primary completion	1 February 2029
Estimated completion	1 February 2044

Drugs / interventions tested

TCR1020-CD8 T cells — full drug profile →

Conditions studied

Metastatic Pancreatic Adenocarcinoma — all drugs for Metastatic Pancreatic Adenocarcinoma →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

University of Pennsylvania

Who can join

18 and older, any sex, with Metastatic Pancreatic Adenocarcinoma or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1020-CD8 T cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma or colorectal cancer will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer.
Miao R, Yu J, Kim RD. · · 2025 · cited 8× · PMID 40361439 · DOI 10.3390/cancers17091512
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
Peng C, Oberstein PE. · · 2025 · cited 1× · PMID 40884689 · DOI 10.1007/s11864-025-01352-2

Verify or expand the search:

Other recruiting trials for Metastatic Pancreatic Adenocarcinoma

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07226856 — BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent P · Phase 2 · recruiting
NCT07189195 — TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory · Phase 1 · recruiting
NCT06396091 — A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer · Phase 1 · active not recruiting
NCT06381154 — Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or · Phase 2 · recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06707896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 25 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06707896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing